CA-SCIENTIST.COM
26.5.2021 13:57:05 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i® , the company’s new supplier pre-assessment program, has officially launched with the successful completion of an on-site assessment of Boca Biolistics’s biorepository facilities. VERIF.i was developed to help both sides of the Scientist.com marketplace. Pre-assessments help suppliers such as Boca Biolistics demonstrate their quality and capabilities, while helping pharma and biotech customers select regulated services in an accelerated manner with more confidence and less risk.
“We have always been confident in the quality of our facilities and the personnel that operate them,” stated Joseph Mauro, Chief Vision Officer at Boca Biolistics. “VERIF.i allows us to demonstrate our expertise to current and future clients of Scientist.com’s marketplace as well as to our existing clientele outside of the platform."
Boca Biolistics is a hybrid contract research organization (CRO) with an integrated life science biorepository, offering central laboratory testing as well as clinical trial services. The company procures human biospecimens from around the world for commercial product development and the advancement of precision medicine. VERIF.i enables Boca Biolistics and other suppliers of regulated research services to communicate their standards against pre-defined criteria developed for the biopharma industry and then confirm them through independent, third-party auditors that carry out an on-site inspection.
“On-site assessments are expensive, resource intensive and time consuming for customers and suppliers,” stated Matt McLoughlin, Sr. VP of Categories and Compliance at Scientist.com. “VERIF.i standardizes and simplifies the process for both sides of the market. It enables suppliers to differentiate themselves from their peers while enabling customers to gain valuable, unbiased insight into a supplier’s facilities, personnel and processes."
VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/
About Boca Biolistics
Boca Biolistics is a hybrid CRO leveraging our vertically integrated model to build a life sciences biorepository with industry leading clinical and molecular data sets. Our commercial biobank has >800,000 specimens available for use in R&D as well as clinical trials. Our CLIA/CAP accredited reference lab offers clinical testing as well as research testing services for diagnostic and pharma. Our CRO division provides end-to-end services for both diagnostic and biopharma clinical trials.
Visit bocabio.com to learn more.
Join us on our LinkedIn page.
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005020/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors17.4.2026 09:04:00 CEST | Press release
The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme. Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing. Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible. “BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS
Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi17.4.2026 09:00:00 CEST | Press release
News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran’s SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran’s focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network’ and ‘Artificial intelligence (AI), machine learning and other software.’ Organized by FTTH Council Europe, the annual awards honor technologies that advance fiber deployment while improving scalability, operational efficiency and user experience. Voted by FTTH Conference 2026 speakers, the results reflect peer recognition for Mosai
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release
- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate
Andersen Global lancerer Andersen in Pakistan16.4.2026 22:57:00 CEST | Pressemeddelelse
Andersen Global fortsætter sin regionale vækst i Sydasien med tilføjelsen af Andersen in Pakistan som det seneste medlemsfirma, der slutter sig til den globale organisation. Efter overgangen til Andersen-brandet tilbyder virksomheden – tidligere kendt som Saafin Global Consulting – en bredt funderet praksis, der betjener kunder på tværs af brancher, herunder fremstillingsindustri, energi, finansielle tjenester, telekommunikation, sundhedsvæsen, fast ejendom og private equity. Med hovedkvarter i Islamabad leverer Andersen in Pakistan integreret support inden for skat, virksomhedsrådgivning og HR-tjenester til nationale og internationale organisationer. "Vores service er forankret i etik, styret af gennemsigtighed og bevist gennem et vedholdende engagement i præcision," udtalte Rashid Ibrahim, ledende partner hos Andersen in Pakistan. "At tage Andersen-brandet til os er en vigtig milepæl for vores firma. Det afspejler vores forpligtelse til at levere praktiske løsninger af høj kvalitet,
BTG Pactual Timberland Investment Group Completes First Close of US$ 370 Million to Newest Core Latin American Timberland Strategy16.4.2026 22:04:00 CEST | Press release
BTG Pactual Timberland Investment Group (BTG Pactual TIG), one of the world’s largest timberland investment managers, announced today that it has completed the first close of US$ 370 million in commitments to its newest core Latin America strategy. Targeting investment of US$ 1.5 billion over 5 years, the strategy focuses on large-scale, sustainably managed, core timberland assets across Chile, Uruguay and Brazil, and seeks diversification across geography, climatic zones, species, and end-markets. BTG Pactual TIG has operated in Latin America for over two decades, and has built and managed a series of scaled timberland platforms through this strategy, including the creation of three platform companies, Lumin, Vista Hermosa, and Plateau, forming part of the firm’s global US$ 7.5 billion portfolio. The formation of Plateau, announced in August 2025, marked the first acquisition under this new strategy. Created in partnership with Klabin S.A. (Klabin) and British Columbia Investment Mana
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom